Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.44 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1831690 | 0.82 | ENPP2 (0.46) | ENPP2TGM2ATMPTGS2CA12 | |
| SCHEMBL24134495 | 0.80 | CA12 (0.35) | TGM2CA12CA1CA2CA9 | |
| SCHEMBL25667539 | 0.80 | ENPP2 (0.54) | ENPP2TGM2ATMCA12CA1 | |
| SCHEMBL2376239 | 0.79 | ENPP2 (0.72) | ENPP2PTGS2 | |
| SCHEMBL2017578 | 0.78 | CA12 (0.64) | ENPP2TGM2ATMPTGS2CA12 | |
| SCHEMBL9246895 | 0.76 | ENPP2 (0.50) | ENPP2ATMPTGS2CA1CA2 | |
| SCHEMBL486575 | 0.76 | CA12 (0.64) | ENPP2TGM2ATMPTGS2CA12 | |
| SCHEMBL23129682 | 0.76 | ENPP2 (0.50) | ENPP2TGM2ATMAVPR2GPR27 | |
| SCHEMBL8916600 | 0.76 | LMNA (0.52) | CA12CA1CA2CA9 | |
| SCHEMBL28044035 | 0.76 | ENPP2 (0.50) | ENPP2TGM2ATMAVPR2GPR27 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102558155-A | Aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of diseases related thereto, such as diabetes and hyperglycemia | ARENA PHARM INC | 2012-07-11 | — | — | CN | claimed |
| CN-109862896-A | For treating the Oxymethylene aryl compound of inflammatory gastrointestinal disease or gastrointestinal disorder | 西玛贝医药公司 | 2019-06-07 | — | — | CN | disclosed |
| CN-107001271-B | Hydroxyamidine derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2019-05-10 | — | — | CN | disclosed |
| CN-106132934-B | The benzimidizole derivatives and its medical composition for treating inflammatory conditions | 加拉帕戈斯股份有限公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-107001271-A | Hydroxyamidine derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2017-08-01 | — | — | CN | disclosed |
| US-8907095-B2 | Bicyclic heterocycle derivatives and their use as modulators of the activity of GPR119 | MERCK SHARP & DOHME CORP. (US) | 2014-12-09 | — | — | US | disclosed |
| CN-101616586-B | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | CYMABAY THERAPEUTICS INC | 2014-08-13 | — | — | CN | disclosed |
| CN-102026636-B | Oxymethylene aryl compounds and uses thereof | METABOLEX INC | 2014-07-16 | — | — | CN | disclosed |
| CN-103611161-A | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARM INC | 2014-03-05 | — | — | CN | disclosed |
| CN-102558155-A | Aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of diseases related thereto, such as diabetes and hyperglycemia | ARENA PHARM INC | 2012-07-11 | — | — | CN | disclosed |
| US-20110212938-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | SCHERING CORPORATION | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212938-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | GPR119, GPR88, GPR180 | ENPP2 606/4885TGM2 1203/4885ATM 4429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.